U.S. Stock Market Movement: Moderna plunges on October 26; Melanoma vaccine data diverges and overall survival rate remains insignificant

Interpretation of Moderna's Sharp Drop on October 26

Keywords: Melanoma vaccine data divergence, overall survival not significant

1. On October 24, detailed Phase III data for the melanoma adjuvant therapy vaccine INTerpath-001, developed by Moderna and Merck, was released. Although there were no results supporting recurrence-free survival, the data showed weak performance in distant metastasis-free survival and no significant difference in overall survival, diminishing the overall persuasiveness of the results.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)